The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.
本发明涉及式(I)的新型M1激动化合物及其在治疗与精神分裂症等疾病相关的认知障碍以及在治疗其他通过
胆碱能M1受体介导的疾病中的应用。